Table 1.
List of selected drugs indicated in solid tumours
| INN | Brand name | MA date | Tumour type |
|---|---|---|---|
| Abiraterone acetate | Zytiga® | 05/09/2011 | Prostate |
| Afatinib | Giotrif® | 25/09/2013 | Lung |
| Aflibercept | Zaltrap® | 01/02/2013 | Colorectal tract |
| Axitinib | Inlyta® | 03/09/2012 | Kidney |
| Cabazitaxel | Jevtana® | 17/03/2011 | Prostate |
| Cabozantinib | Cometriq® | 21/03/2014 | Thyroid |
| Catumaxomab | Removab® | 20/04/2009 | Ascites |
| Crizotinib | Xalkori® | 23/10/2012 | Lung |
| Dabrafenib | Tafinlar® | 26/08/2013 | Skin |
| Degarelix | Firmagon® | 17/02/2009 | Prostate |
| Enzalutamide | Xtandi® | 21/06/2013 | Prostate |
| Eribulin | Halaven® | 17/03/2011 | Breast |
| Everolimus | Afinitor® | 03/08/2009 | Breast, pancreas and kidney |
| Gefitinib | Iressa® | 24/06/2009 | Lung |
| Ipilimumab | Yervoy® | 13/07/2011 | Skin |
| Mifamurtide | Mepact® | 06/03/2009 | Bones |
| Nintedanib | Vargatef® | 21/11/2014 | Lung |
| Olaparib | Lynparza® | 16/12/2014 | Ovaries, fallopian tubes and peritonea |
| Pazopanib | Votrient® | 14/06/2010 | Kidney and soft-tissue |
| Pertuzumab | Perjeta® | 04/03/2013 | Breast |
| Radium Ra223 dichloride | Xofigo® | 13/11/2013 | Prostate |
| Ramucirumab | Cyramza® | 19/12/2014 | Gastro-oesophageal tract |
| Regorafenib | Stivarga® | 26/08/2013 | Colorectal tract |
| Sipuleucel-T | Provenge® | 06/09/2013 | Prostate |
| Tegafur/Gimeracil/Oteracil | Teysuno® | 14/03/2011 | Gastro-oesophageal tract |
| Trametinib | Mekinist® | 30/06/2014 | Skin |
| Trastuzumab emtansine | Kadcyla® | 15/11/2013 | Breast |
| Vandetanib | Caprelsa® | 17/02/2012 | Thyroid |
| Vemurafenib | Zelboraf® | 17/02/2012 | Skin |
| Vinflunine | Javlor® | 21/09/2009 | Urothelial tract |
| Vismodegib | Erivedge® | 12/07/2013 | Basal cells |